The COVID-19 pandemic and the use of MS disease-modifying therapies

Affiliations

¹ Blizard Institute, Barts and The London School of Medicine and Dentistry, 4 Newark Street, London, E1 2AT, UK. Electronic address: g.giovannoni@qmul.ac.uk.
² Blizard Institute, Barts and The London School of Medicine and Dentistry, 4 Newark Street, London, E1 2AT, UK.
³ School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia.
⁴ NMO Clinic and Research Laboratory, Division of Neuroimmunology & Neuroinfectious Disease, Massachusetts General Hospital, Boston, USA.
⁵ Department of Neurology, UC San Francisco, San Francisco, California, USA.
⁶ Blizard Institute, Barts and The London School of Medicine and Dentistry, 4 Newark Street, London, E1 2AT, UK; The Albion Centre, Prince of Wales Hospital, Sydney, New South Wales, Australia.

Gavin Giovannoni et al. Mult Scler Relat Disord. 2020 Apr.

. 2020 Apr:39:102073.

doi: 10.1016/j.msard.2020.102073. Epub 2020 Mar 27.

¹ Blizard Institute, Barts and The London School of Medicine and Dentistry, 4 Newark Street, London, E1 2AT, UK. Electronic address: g.giovannoni@qmul.ac.uk.
² Blizard Institute, Barts and The London School of Medicine and Dentistry, 4 Newark Street, London, E1 2AT, UK.
³ School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia.
⁴ NMO Clinic and Research Laboratory, Division of Neuroimmunology & Neuroinfectious Disease, Massachusetts General Hospital, Boston, USA.
⁵ Department of Neurology, UC San Francisco, San Francisco, California, USA.
⁶ Blizard Institute, Barts and The London School of Medicine and Dentistry, 4 Newark Street, London, E1 2AT, UK; The Albion Centre, Prince of Wales Hospital, Sydney, New South Wales, Australia.

No abstract available

Comment in

The big challenge for neurologists in treating patients with multiple sclerosis in the post-COVID-19 era.
Naser Moghadasi A. Naser Moghadasi A. Mult Scler Relat Disord. 2020 Jul;42:102170. doi: 10.1016/j.msard.2020.102170. Epub 2020 May 1. Mult Scler Relat Disord. 2020. PMID: 32403068 Free PMC article. No abstract available.

1. Andersen K.G., Rambaut A., Ian Lipkin W., Holmes E.C., Garry R.F. The proximal origin of SARS-CoV-2. Nat. Med. 2020 doi: 10.1038/s41591-020-0820-9. https://doi.org/ - DOI - PMC - PubMed
1. Arbour N., Côté G., Lachance C., Tardieu M., Cashman N.R., Talbot P.J. Acute and persistent infection of human neural cell lines by human coronavirus OC43. J. Virol. 1999;73:3338–3350. - PMC - PubMed
1. Cook S., Vermersch P., Comi G., Giovannoni G., Rammohan K., Rieckmann P., Sørensen P.S., Hamlett A., Miret M., Weiner J., Viglietta V., Musch B., Greenberg S.J., CLARITY Study Group Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. Mult. Scler. 2011;17:578–593. - PubMed
1. Epstein D.J., Dunn J., Deresinski S. Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management. Open Forum Infect. Dis. 2018;5:ofy174. - PMC - PubMed
1. Fine A.J., Sorbello A., Kortepeter C., Scarazzini L. Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients. Clin. Infect. Dis. 2013;57:849–852. - PubMed